Spero Therapeutics Announces Pricing of Securities Offering

CAMBRIDGE, Mass. , July 12, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the pricing of an

READ FULL TEXT

Leave a Reply

Your email address will not be published.